EcoDrugPlus

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSHCOG00000021129
Gene Symbol: HCN4
3 Cross references
221 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSHCOG00000000473
Gene Symbol: HCN4
4 Cross references
212 Possible Orthologues:

Hypocretin Receptor 2

Ensembl ID : ENSHCOG00000015610
Gene Symbol: HCRTR2
3 Cross references
203 Possible Orthologues:

Ileal Sodium/bile Acid Cotransporter-Like

Ensembl ID : ENSHCOG00000005174
Gene Symbol: LOC109519735
3 Cross references
213 Possible Orthologues:

Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1-Like

Ensembl ID : ENSHCOG00000015084
Gene Symbol: LOC109520706
3 Cross references
209 Possible Orthologues:

Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1-Like

Ensembl ID : ENSHCOG00000013101
Gene Symbol: LOC109512183
3 Cross references
209 Possible Orthologues:

Inhibitor Of Nuclear Factor Kappa-B Kinase Subunit Beta-Like

Ensembl ID : ENSHCOG00000007550
Gene Symbol: LOC109525796
3 Cross references
199 Possible Orthologues:

Inosine Monophosphate Dehydrogenase 2

Ensembl ID : ENSHCOG00000007092
Gene Symbol: IMPDH2
4 Cross references
200 Possible Orthologues:

Inosine-5'-Monophosphate Dehydrogenase 1b

Ensembl ID : ENSHCOG00000010528
Gene Symbol: LOC109526723
4 Cross references
258 Possible Orthologues:

Inositol Polyphosphate-5-Phosphatase D

Ensembl ID : ENSHCOG00000014071
Gene Symbol: INPP5D
3 Cross references
215 Possible Orthologues:

Insulin Like Growth Factor 1 Receptor

Ensembl ID : ENSHCOG00000001494
Gene Symbol: IGF1R
3 Cross references
203 Possible Orthologues:

Insulin Receptor-Like

Ensembl ID : ENSHCOG00000020384
Gene Symbol: LOC109522033
3 Cross references
212 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).